NEW YORK — When patients with multiple myeloma (MM) relapse following chimeric antigen receptor (CAR) T-cell therapy, bispecific antibodies (BsABs), or both, likely salvage options remain […]

The incidence of lung cancer in never-smokers (LCINS) is increasing, and experts think climate change may be driving this. LCINS differs histologically and epidemiologically from smoking-related […]

NEW YORK — In a three-way debate on whether to prioritize chimeric antigen receptor (CAR) T-cell therapy, bispecific antibodies (BsAbs), or one of the novel oral […]

NEW YORK — In the wake of details about the molecular pathophysiology of Waldenström macroglobulinemia (WM), an expert gave an update on current and expanding options […]

Adding a second checkpoint inhibitor to chemotherapy improves outcomes among patients with non–small cell lung cancer (NSCLC) who have STK11 and/or KEAP1 mutations, according to the authors […]

For more than three decades, the federal government sought to make amends to countless Americans who developed cancer after being exposed to radiation from nuclear testing […]

SAN FRANCISCO — While the physical toll of cancer is well documented, the financial toll can also be severe and lasting. Overall, patients with cancer tend […]